Figure 2.

Proteasome inhibition stabilizes exogenously expressed BikDD. A. Three BikDD stable cell lines were treated with MG132 for 8 hours and their BikDD expression levels were analyzed by Western blot. B-D. BikDD was transiently expressed in MIA PaCa-2 and L3.6pL pancreatic and MDA-MB-231 breast cancer cells for 24 hours. Cells were then treated with proteasome inhibitors, MG132 or bortezomib (BZ), at the indicated concentration(s) for 8 hours. Cell lysates were subjected to Western blot analysis to evaluate the effect of proteasome inhibition.